GSK Blood Cancer Drug Issues

News

GSK, food and drug administration

FDA advisers say risks of GSK blood cancer drug outweigh benefits in surprise setback

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the selected dose

Reuters on MSN · 3d

GSK falls as blood cancer drug likely headed for US rejection

(Reuters) -GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier concerns over side effects.

Medical Dialogues · 5d

GSK blood cancer drug Blenrep faces USFDA scrutiny over vision issues

GSK's blood cancer drug, Blenrep, is under the U.S. Food and Drug Administration (USFDA) spotlight, as staff reviewers raised safety concerns on Tuesday that the drug, when used in combination

STAT3d

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

Wall Street Journal7mon

GSK Gets Positive Results in Blood-Cancer Drug Trial - WSJ

GSK ’s GSK -3.16% blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the likelihood for the treatment to return to market next year. The data ...

AOL7mon

GSK's Blood Cancer Drug Shows Improved Survival Compared To ... - AOL

GSK (GSK): Free Stock Analysis Report This article GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex originally appeared on Benzinga.com ...

The Financial Times8mon

GSK hails progress for withdrawn blood cancer drug

GSK hailed progress for its withdrawn blood cancer drug Blenrep on Thursday, raising the prospect of the treatment returning to market after the drugmaker announced positive trial results.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results